<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.comparative-hepatology.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Comparative Hepatology - Most accessed articles</title>
        <link>http://www.comparative-hepatology.com</link>
        <description>The most accessed research articles published by Comparative Hepatology</description>
        <dc:date>2010-08-20T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/6/1/7" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/9/1/7" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/2/1/4" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/2/1/7" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/9/1/5" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/9/1/4" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/9/1/3" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/9/1/1" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/9/1/6" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/8/1/5" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.comparative-hepatology.com/content/6/1/7">
        <title>Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options</title>
        <description>Despite intensive studies, the clinical opportunities for patients with fibrosing liver diseases have not improved. This will be changed by increasing knowledge of new pathogenetic mechanisms, which complement the &quot;canonical principle&quot; of fibrogenesis. The latter is based on the activation of hepatic stellate cells and their transdifferentiation to myofibroblasts induced by hepatocellular injury and consecutive inflammatory mediators such as TGF-&#946;. Stellate cells express a broad spectrum of matrix components. New mechanisms indicate that the heterogeneous pool of (myo-)fibroblasts can be supplemented by epithelial-mesenchymal transition (EMT) from cholangiocytes and potentially also from hepatocytes to fibroblasts, by influx of bone marrow-derived fibrocytes in the damaged liver tissue and by differentiation of a subgroup of monocytes to fibroblasts after homing in the damaged tissue. These processes are regulated by the cytokines TGF-&#946; and BMP-7, chemokines, colony-stimulating factors, metalloproteinases and numerous trapping proteins. They offer innovative diagnostic and therapeutic options. As an example, modulation of TGF-&#946;/BMP-7 ratio changes the rate of EMT, and so the simultaneous determination of these parameters and of connective tissue growth factor (CTGF) in serum might provide information on fibrogenic activity. The extension of pathogenetic concepts of fibrosis will provide new therapeutic possibilities of interference with the fibrogenic mechanism in liver and other organs.</description>
        <link>http://www.comparative-hepatology.com/content/6/1/7</link>
                <dc:creator>Olav Gressner</dc:creator>
                <dc:creator>Ralf Weiskirchen</dc:creator>
                <dc:creator>Axel Gressner</dc:creator>
                <dc:source>Comparative Hepatology 2007, 6:7</dc:source>
        <dc:date>2007-07-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-6-7</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2007-07-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/9/1/7">
        <title>Adoptive transfer of splenocytes to study cell-mediated immune responses in hepatitis C infection using HCV transgenic mice</title>
        <description>Background:
Hepatitis C virus (HCV) is a major cause of chronic hepatitis and a health problem affecting over 170 million people around the world. We previously studied transgenic mice that express HCV Core, Envelope 1 and Envelope 2 proteins predominantly in the liver, resulting in steatosis, liver and lymphoid tumors, and hepatocellular carcinoma. Herein, the immune-mediated cell response to  hepatitis C antigens was evaluated by adoptive transfers of carboxyfluorescein succinimidyl ester (CFSE) labelled splenocytes from HCV immunized mice into HCV transgenic mice.
Results:
In comparison to non-transgenic mice, there was a significant decrease in the percentage of CFSE-labeled CD4+ and CD8+ T cells in transgenic mouse peripheral blood receiving adoptive transfers from immunized donors. Moreover, the percentage of CFSE-labeled CD4+ and CD8+ T cells were significantly higher in the spleen of transgenic and non-transgenic mice when they received splenocytes from non-immunized than from immunized mice. On the other hand, the percentages of CD4+ and CD8+ T cells in the non-transgenic recipient mouse lymph nodes were significantly higher than the transgenic mice when they received the adoptive transfer from immunized donors. Interestingly, livers of transgenic mice that received transfers from immunized mice had a significantly higher percentage of CFSE labeled T cells than livers of non-transgenic mice receiving non-immunized transfers.
Conclusions:
These results suggest that the T cells from HCV immunized mice recognize the HCV proteins in the liver of the transgenic mouse model and homed to the HCV antigen expression sites. We propose using this model system to study active T cell responses in HCV infection.</description>
        <link>http://www.comparative-hepatology.com/content/9/1/7</link>
                <dc:creator>Turaya Naas</dc:creator>
                <dc:creator>Masoud Ghorbani</dc:creator>
                <dc:creator>Catalina Soare</dc:creator>
                <dc:creator>Nicole Sherling</dc:creator>
                <dc:creator>Rudy Muller</dc:creator>
                <dc:creator>Peyman Ghorbani</dc:creator>
                <dc:creator>Francisco Diaz-Mitoma</dc:creator>
                <dc:source>Comparative Hepatology 2010, 9:7</dc:source>
        <dc:date>2010-08-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-9-7</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2010-08-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/2/1/4">
        <title>Eggshell and egg yolk proteins in fish: hepatic proteins for the next generation: oogenetic, population, and evolutionary implications of endocrine disruption</title>
        <description>The oocyte is the starting point for a new generation. Most of the machinery for DNA and protein synthesis needed for the developing embryo is made autonomously by the fertilized oocyte. However, in fish and in many other oviparous vertebrates, the major constituents of the egg, i.e. yolk and eggshell proteins, are synthesized in the liver and transported to the oocyte for uptake. Vitellogenesis, the process of yolk protein (vitellogenin) synthesis, transport, and uptake into the oocyte, and zonagenesis, the synthesis of eggshell zona radiata proteins, their transport and deposition by the maturing oocyte, are important aspects of oogenesis. The many molecular events involved in these processes require tight, coordinated regulation that is under strict endocrine control, with the female sex steroid hormone estradiol-17&#946; in a central role. The ability of many synthetic chemical compounds to mimic this estrogen can lead to unscheduled hepatic synthesis of vitellogenin and zona radiata proteins, with potentially detrimental effects to the adult, the egg, the developing embryo and, hence, to the recruitment to the fish population. This has led to the development of specific and sensitive assays for these proteins in fish, and the application of vitellogenin and zona radiata proteins as informative biomarkers for endocrine disrupting effects of chemicals and effluents using fish as test organisms. The genes encoding these important reproductive proteins are conserved in the animal kingdom and are products of several hundred million years of evolution.</description>
        <link>http://www.comparative-hepatology.com/content/2/1/4</link>
                <dc:creator>Augustine Arukwe</dc:creator>
                <dc:creator>Anders Goksoyr</dc:creator>
                <dc:source>Comparative Hepatology 2003, 2:4</dc:source>
        <dc:date>2003-03-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-2-4</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2003-03-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/2/1/7">
        <title>FNH-like nodules: Possible precursor lesions in patients with focal nodular hyperplasia (FNH)</title>
        <description>Background:
The typical lesion of focal nodular hyperplasia (FNH) is a benign tumor-like mass characterized by hepatocytic nodules separated by fibrous bands. The solitary central artery with high flow and the absent portal vein give the lesions their characteristic radiological appearance. The great majority of cases seen in daily practice conform to the above description. Additional small nodules (from 1-2 up to 15-20 mm in diameter) detected by imaging techniques or on macroscopic examination may be difficult to identify as representing FNH if they lack the key features of FNH as defined in larger lesions. The aim of this study was to characterize these small nodules, and to compare their characteristics with those of typical lesions of FNH present in the same specimens.
Results:
Eight patients underwent hepatic resections for the removal of a mass lesion (&quot;nodule&quot;) diagnosed as: FNH (1 patient); nodules of unknown nature (5 patients); or nodules thought to be adenoma or hepatocellular carcinoma (2 patients). Six nodules out of 9 discovered by imaging techniques met histopathological criteria for the diagnosis of typical FNH, at least in parts of the nodule; 2 nodules corresponded to a minor form of FNH (&quot;subtle FNH&quot;) and one nodule to a steatotic area. Although FNH was thought to be found in a normal or nearly normal liver, this study revealed that, in addition, there were various types of small FNH-like nodules and vascular abnormalities in the liver with typical FNH nodule. The various types of small FNH-like nodules (n = 8, diameter 2 to 20 mm) consisted of the association to various degrees of numerous and/or enlarged arteries in portal tracts or in septa, with hyperplastic foci, slight ductular reaction, and regions of sinusoidal dilatation, accompanied by thin fibrous bands. Vascular abnormalities consisted of unpaired arteries, portal tracts with arteries larger than the associated bile duct, and regions of sinusoidal dilatation.
Conclusions:
Although these small nodules can be considered as insufficient type or abortive forms of FNH, or adenoma, they can be precursors of the large mass lesions in which FNH was recognized and defined.</description>
        <link>http://www.comparative-hepatology.com/content/2/1/7</link>
                <dc:creator>Sebastien Lepreux</dc:creator>
                <dc:creator>Christophe Laurent</dc:creator>
                <dc:creator>Charles Balabaud</dc:creator>
                <dc:creator>Paulette Bioulac-Sage</dc:creator>
                <dc:source>Comparative Hepatology 2003, 2:7</dc:source>
        <dc:date>2003-06-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-2-7</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2003-06-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/9/1/5">
        <title>Daytime food restriction alters liver glycogen, triacylglycerols, and cell size: a histochemical, morphometric, and ultrastructural study</title>
        <description>Background:
Temporal restriction of food availability entrains circadian behavioral and physiological rhythms in mammals by resetting peripheral oscillators. This entrainment underlies the activity of a timing system, different from the suprachiasmatic nuclei (SCN), known as the food entrainable oscillator (FEO). So far, the precise anatomical location of the FEO is unknown. The expression of this oscillator is associated with an enhanced arousal prior to the food presentation that is called food anticipatory activity (FAA). We have focused on the study of the role played by the liver as a probable component of the FEO. The aim of this work was to identify metabolic and structural adaptations in the liver during the expression of the FEO, as revealed by histochemical assessment of hepatic glycogen and triacylglycerol contents, morphometry, and ultrastructure in rats under restricted feeding schedules (RFS).
Results:
RFS promoted a decrease in the liver/body weight ratio prior to food access, a reduction of hepatic water content, an increase in cross-sectional area of the hepatocytes, a moderate reduction in glycogen content, and a striking decrease in triacylglyceride levels. Although these adaptation effects were also observed when the animal displayed FAA, they were reversed upon feeding. Mitochondria observed by electron microscopy showed a notorious opacity in the hepatocytes from rats during FAA (11:00 h). Twenty four hour fasting rats did not show any of the modifications observed in the animals expressing the FEO.
Conclusions:
Our results demonstrate that FEO expression is associated with modified liver handling of glycogen and triacylglycerides accompanied by morphometric and ultrastructural adaptations in the hepatocytes. Because the cellular changes detected in the liver cannot be attributed to a simple alternation between feeding and fasting conditions, they also strengthen the notion that RFS promotes a rheostatic adjustment in liver physiology during FEO expression.</description>
        <link>http://www.comparative-hepatology.com/content/9/1/5</link>
                <dc:creator>Mauricio Diaz-Munoz</dc:creator>
                <dc:creator>Olivia Vazquez-Martinez</dc:creator>
                <dc:creator>Adrian Baez-Ruiz</dc:creator>
                <dc:creator>Gema Martinez-Cabrera</dc:creator>
                <dc:creator>Maria Soto-Abraham</dc:creator>
                <dc:creator>Maria Avila-Casado</dc:creator>
                <dc:creator>Jorge Larriva-Sahd</dc:creator>
                <dc:source>Comparative Hepatology 2010, 9:5</dc:source>
        <dc:date>2010-02-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-9-5</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2010-02-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/9/1/4">
        <title>Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours</title>
        <description>Background:
The expression of Keratin 19 (K19) was reported in a subset of hepatocellular carcinomas (HCCs). K19 positive HCCs are associated with an increased malignancy compared to K19 negative HCCs. No suitable mouse models exist for this subtype of HCC, nor is the incidence of K19 expression in hepatocellular neoplasia in model animals known. Therefore, we compared the occurrence and tumour behaviour of K19 positive hepatocellular neoplasias in dog and man.
Results:
The expression of hepatocellular differentiation (HepPar-1), biliary/progenitor cell (K7, K19), and malignancy (glypican-3) markers was semi-quantitatively assessed by immunohistochemistry. The histological grade of tumour differentiation was determined according to a modified classification of Edmondson and Steiner; the staging included intrahepatic, lymph node or distant metastases. Four of the 34 canine hepatocellular neoplasias showed K19 positivity (12%), of which two co-expressed K7. K19 positive tumours did not express HepPar-1, despite the histological evidence of a hepatocellular origin. Like in human HCC, all K19 positive hepatocellular neoplasias were glypican-3 positive and histologically poorly differentiated and revealed intra- or extrahepatic metastases whereas K19 negative hepatocellular neoplasias did not.
Conclusions:
K19 positive hepatocellular neoplasias are highly comparable to man and occur in 12% of canine hepatocellular tumours and are associated with a poorly differentiated histology and aggressive tumour behaviour.</description>
        <link>http://www.comparative-hepatology.com/content/9/1/4</link>
                <dc:creator>Renee van Sprundel</dc:creator>
                <dc:creator>Ted van den Ingh</dc:creator>
                <dc:creator>Valeer Desmet</dc:creator>
                <dc:creator>Aezam Katoonizadeh</dc:creator>
                <dc:creator>Louis Penning</dc:creator>
                <dc:creator>Jan Rothuizen</dc:creator>
                <dc:creator>Tania Roskams</dc:creator>
                <dc:creator>Bart Spee</dc:creator>
                <dc:source>Comparative Hepatology 2010, 9:4</dc:source>
        <dc:date>2010-02-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-9-4</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2010-02-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/9/1/3">
        <title>Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatin</title>
        <description>Background:
Perihepatitis is rare but consistently occurring extragenital manifestation of untreated Chlamydia trachomatis infection. Despite of possible liver involvement in generalized C. trachomatis infection, the ability of the pathogen to propagate in the hepatic cells and its impact on liver functions is not thoroughly investigated. The effect of mevastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, on C. trachomatis growth in human hepatoma cell line HepG2 has been studied. Bacterial growth was assessed by immunostaining with FITC-labeled monoclonal antibody against chlamydial lipopolysaccharide and by RT-PCR for two chlamydial genetic markers (16S rRNA and euo).
Results:
Chlamydial inclusion bodies were seen in approximately 50% of hepatocytes at 48 hours in the post infection period. Lysates obtained from infected hepatocytes were positive in the infective progeny test at 48 and especially in 72 hours after infection initiation. It has been shown that chlamydial infection in hepatocytes also leads to the decline of LDL-receptor mRNA which reflects infection multiplicity rate. Additions of mevastatin (1, 20 and 40 &#956;M) 1 hour before inoculation restored and upregulated LDL-receptor mRNA level in a dose-dependent manner. Mevastatin treatment had no effect on internalization of chlamydial particles. However it reduced drastically the number of chlamydial 16S rRNA and euo transcripts as well as overall infection rate in HepG-2 cells. Complete eradication of infection has been seen by immunofluorescent staining at 40 &#956;M mevastatin concentration, when expression level of chlamydial 16S rRNA and euo was undetectable. Lower concentration of mevastatin (20 &#956;M) promoted euo expression level and the appearance of atypically small chlamydial inclusions, while there was a noticeable reduction in the number of infected cells and 16S rRNA transcripts.
Conclusions:
C. trachomatis can efficiently propagate in hepatocytes affecting transcription rate of some liver-specific genes. Ongoing cholesterol synthesis is essential for chlamydial growth in hepatocytes. Inhibitors of cholesterol biosynthesis can supplement conventional strategy in the management of C. trachomatis infection.</description>
        <link>http://www.comparative-hepatology.com/content/9/1/3</link>
                <dc:creator>Yuriy Bashmakov</dc:creator>
                <dc:creator>Nailya Zigangirova</dc:creator>
                <dc:creator>Yulia Pashko</dc:creator>
                <dc:creator>Lidia Kapotina</dc:creator>
                <dc:creator>Ivan Petyaev</dc:creator>
                <dc:source>Comparative Hepatology 2010, 9:3</dc:source>
        <dc:date>2010-01-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-9-3</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-01-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/9/1/1">
        <title>Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4</title>
        <description>Background:
Liver disease progression from chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) is associated with an imbalance between T-helper 1 and T-helper 2 cytokines. Evaluation of cytokines as possible candidate biomarkers for prediction of HCC was performed using soluble Fas (sFas), soluble tumor necrosis factor receptor-II (sTNFR-II), interleukin-2 receptor (IL-2R) and interleukin-8 (IL-8).
Results:
The following patients were recruited: 79 with HCV infection, 30 with HCC, 32 with chronic liver disease associated with elevated liver enzyme levels (with or without cirrhosis) in addition to 17 with chronic HCV with persistent normal alanine aminotransferase levels (PNALT). Nine normal persons negative either for HCV or for hepatitis B virus were included as a control group. All persons were tested for sFas, sTNFR-II, IL-2R and IL-8 in their serum by quantitative ELISA. HCC patients had higher levels of liver enzymes but lower log-HCV titer when compared to the other groups. HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and significantly lower levels of IL-8 when compared to the other groups. Exclusion of HCC among patients having PNALT could be predicted with 90% sensitivity and 70.6% specificity when sTNFR-II is &#8805; 389 pg/ml or IL-8 is &lt; 290 pg/ml.
Conclusions:
Serum TNFR-II, IL-2R&#945; and IL-8, may be used as combined markers in HCV-infected cases for patients at high risk of developing HCC; further studies, however, are mandatory to check these findings before their application at the population level.</description>
        <link>http://www.comparative-hepatology.com/content/9/1/1</link>
                <dc:creator>Abdel-Rahman Zekri</dc:creator>
                <dc:creator>Hanaa Alam El-Din</dc:creator>
                <dc:creator>Abeer Bahnassy</dc:creator>
                <dc:creator>Naglaa Zayed</dc:creator>
                <dc:creator>Waleed Mohamed</dc:creator>
                <dc:creator>Suzan El-Masry</dc:creator>
                <dc:creator>Sayed Gouda</dc:creator>
                <dc:creator>Gamal Esmat</dc:creator>
                <dc:source>Comparative Hepatology 2010, 9:1</dc:source>
        <dc:date>2010-01-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-9-1</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-01-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/9/1/6">
        <title>An insertion mutation in ABCB4 is associated with gallbladder mucocele formation in dogs</title>
        <description>Background:
ABCB4 functions as a phosphatidylcholine translocater, flipping phosphatidylcholine across hepatocyte canalicular membranes into biliary canaliculi. In people, ABCB4 gene mutations are associated with several disease syndromes including intrahepatic cholestasis of pregnancy, progressive familial intrahepatic cholestasis (type 3), primary biliary cirrhosis, and cholelithiasis. Hepatobiliary disease, specifically gallbladder mucocele formation, has been recognized with increased frequency in dogs during the past decade. Because Shetland Sheepdogs are considered to be predisposed to gallbladder mucoceles, we initially investigated ABCB4 as a candidate gene for gallbladder mucocele formation in that breed, but included affected dogs of other breeds as well.
Results:
An insertion (G) mutation in exon 12 of canine ABCB4 (ABCB4 1583_1584G) was found to be significantly associated with hepatobiliary disease in Shetland Sheepdogs specifically (P &lt; 0.0001) as well as other breeds (P &lt; 0.0006). ABCB4 1583_1584G results in a frame shift generating four stop codons that prematurely terminate ABCB4 protein synthesis within exon 12, abolishing over half of the protein including critical ATP and a putative substrate binding site.
Conclusions:
The finding of a significant association of ABCB4 1583_1584G with gallbladder mucoceles in dogs suggests that this phospholipid flippase may play a role in the pathophysiology of this disorder. Affected dogs may provide a useful model for identifying novel treatment strategies for ABCB4-associated hepatobiliary disease in people.</description>
        <link>http://www.comparative-hepatology.com/content/9/1/6</link>
                <dc:creator>Katrina Mealey</dc:creator>
                <dc:creator>Jonathan Minch</dc:creator>
                <dc:creator>Stephen White</dc:creator>
                <dc:creator>Kevin Snekvik</dc:creator>
                <dc:creator>John Mattoon</dc:creator>
                <dc:source>Comparative Hepatology 2010, 9:6</dc:source>
        <dc:date>2010-07-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-9-6</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-07-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/8/1/5">
        <title>Immunohistochemical study of the phenotypic change of the mesenchymal cells during portal tract maturation in normal and fibrous (ductal plate malformation) fetal liver</title>
        <description>Background:
In adult liver, the mesenchymal cells, portal fibroblasts and vascular smooth muscle cells can transdifferentiate into myofibroblasts, and are involved in portal fibrosis. Differential expression of markers, such as alpha-smooth muscle actin (ASMA), h-caldesmon and cellular retinol-binding protein-1 allows their phenotypic discrimination. The aim of our study was to explore the phenotypic evolution of the mesenchymal cells during fetal development in normal liver and in liver with portal fibrosis secondary to ductal plate malformation in a series of Meckel-Gruber syndrome, autosomal recessive polycystic kidney disease and Ivemark&apos;s syndrome.
Results:
At the early steps of the portal tract maturation, portal mesenchymal cells expressed only ASMA. During the maturation process, these cells were found condensed around the biliary and vascular structures. At the end of maturation process, only cells around vessels expressed ASMA and cells of the artery tunica media also expressed h-caldesmon. In contrast, ASMA positive cells persisted around the abnormal biliary ducts in fibrous livers.
Conclusion:
As in adult liver, there is a phenotypic heterogeneity of the mesenchymal cells during fetal liver development. During portal tract maturation, myofibroblastic cells disappear in normal development but persist in fibrosis following ductal plate malformation.</description>
        <link>http://www.comparative-hepatology.com/content/8/1/5</link>
                <dc:creator>Julien Villeneuve</dc:creator>
                <dc:creator>Fanny Pelluard-Nehme</dc:creator>
                <dc:creator>Chantal Combe</dc:creator>
                <dc:creator>Dominique Carles</dc:creator>
                <dc:creator>Christine Chaponnier</dc:creator>
                <dc:creator>Jean Ripoche</dc:creator>
                <dc:creator>Charles Balabaud</dc:creator>
                <dc:creator>Paulette Bioulac-Sage</dc:creator>
                <dc:creator>Sebastien Lepreux</dc:creator>
                <dc:source>Comparative Hepatology 2009, 8:5</dc:source>
        <dc:date>2009-07-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-8-5</dc:identifier>
        <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-07-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
